Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen L.; Hansen, Karin Holmskov; Kim, Sang-We; Huber, Rudolf M.; West, Howard L.; Groen, Harry J. M.; Hochmair, Maximilian J.
Published in:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2016.71.5904

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 25-04-2020
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial


ABSTRACT

Purpose
Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK) rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-positive NSCLC.

Patients and Methods
Patients were stratified by brain metastases and best response to crizotinib. They were randomly assigned (1:1) to oral brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg once daily [with lead-in]; arm B). Investigator-assessed confirmed objective response rate (ORR) was the primary end point.

Results
Of 222 patients enrolled (arm A: n = 112, 109 treated; arm B: n = 110, 110 treated), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. With 8.0-month median follow-up, investigator-assessed confirmed ORR was 45% (97.5% CI, 34% to 56%) in arm A and 54% (97.5% CI, 43% to 65%) in arm B. Investigator-assessed median progression-free survival was 9.2 months (95% CI, 7.4 to 15.6) and 12.9 months (95% CI, 11.1 to not reached) in arms A and B, respectively. Independent review committee–assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11 of 26 patients) in arm A and 67% (12 of 18 patients) in arm B. Common treatment-emergent adverse events were nausea (arm A/B, 33%/40%), diarrhea (arm A/B, 19%/38%), headache (arm A/B, 28%/27%), and cough (arm A/B, 18%/34%), and were mainly grades 1 to 2. A subset of pulmonary adverse events with early onset (median onset: day 2) occurred in 14 of 219 treated patients (all grades, 6%; grade $3, 3%); none occurred after escalation to 180 mg in arm B. Seven of 14 patients were successfully retreated with brigatinib.

Conclusion
Brigatinib yielded substantial whole-body and intracranial responses as well as robust progression-free survival; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.

J Clin Oncol 35:2490-2498. © 2017 by American Society of Clinical Oncology

INTRODUCTION

In approximately 5% of patients with non–small-cell lung cancer (NSCLC), anaplastic lymphoma kinase gene (ALK) rearrangements encode an oncogenic fusion protein. Treatment with crizotinib, the first ALK inhibitor approved for use in metastatic ALK-rearranged (ALK-positive) NSCLC, has yielded objective response rates (ORRs) of 61% to 74% and median progression-free survival (PFS) of approximately 8 to 11 months in patients with advanced ALK-positive NSCLC. Most crizotinib-treated patients with ALK-positive NSCLC eventually experience progression, because of acquired changes in the dominant biology of the cancer, poor CNS drug penetration resulting in CNS progression, or both.
Mechanisms of acquired resistance to crizotinib typically involve changes in the ALK gene or activation of signaling pathways that bypass ALK.9,10,11 Second-generation ALK inhibitors currently approved in the postcrizotinib setting, ceritinib and alectinib, have been associated with a median PFS of 5.7 to 6.9 months12-14 and 8.1 to 8.9 months,15,16 respectively. However, secondary ALK kinase domain mutations, including the recalcitrant G1202R mutation, have been identified in patients whose disease progressed with ceritinib or alectinib after crizotinib therapy.17-19 Therefore, additional ALK inhibitors that are effective against (and can suppress the development of) a broader array of ALK mutations are needed.

Brigatinib (AP26113; ARIAD Pharmaceuticals, Cambridge, MA), an investigational next-generation ALK tyrosine kinase inhibitor, was designed for potent activity against a broad range of ALK resistance mutations.20 In preclinical models, brigatinib potently inhibited all ALK resistance mutations tested, including G1202R, and overcame mechanisms of resistance to other ALK inhibitors at clinically achievable brigatinib levels.21 In an ongoing phase I/II clinical trial (NCT01449461), brigatinib yielded promising antitumor activity (confirmed ORR, 62%; median PFS, 12.9 months) in patients with advanced ALK-positive NSCLC previously treated with crizotinib.22 However, during dose escalation and an initial phase II expansion at 180 mg once daily, a small proportion of patients had moderate or severe pulmonary adverse events (AEs) with early onset (usually within 24 to 48 hours) that were observed more frequently at higher starting doses. The phase II expansion therefore explored two additional regimens, 90 mg once daily and 180 mg once daily with a 7-day lead-in at 90 mg (180 mg once daily [with lead-in]). These regimens had similar preliminary activity and acceptable overall safety; 180 mg once daily (with lead-in) seemed to reduce early pulmonary AE frequency while providing greater treatment exposure.22,23

On the basis of phase I/II trial results, we conducted a randomized phase II trial to prospectively assess brigatinib efficacy and safety at 90 mg once daily and 180 mg once daily (with lead-in) in patients with crizotinib-refractory advanced ALK-positive NSCLC.

### Study Design and Patients

The ALK in Lung Cancer Trial of AP26113 (ALTA trial; ClinicalTrials.gov identifier: NCT02094573) is an ongoing open-label, randomized, multicenter, international phase II study. Eligible patients (≥18 years of age) had locally advanced or metastatic ALK-positive NSCLC, investigator-determined disease progression while receiving crizotinib, at least one measurable lesion per Response Evaluation Criteria in Solid Tumors determined disease progression while receiving crizotinib, at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or partial response (PR) v other or unknown) and were randomly assigned (1:1) to 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg (180 mg once daily [with lead-in]; arm B). Treatment continued until disease progression requiring alternative systemic therapy, intolerable toxicity, or consent withdrawal. Treatment in either arm could be continued at the investigator’s discretion after progression. Patients in arm A could receive brigatinib 180 mg once daily after objective progression at 90 mg once daily. Dose interruptions or reductions were allowed to manage treatment-related AEs, on the basis of the investigator’s judgment. AEs were graded with National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

At screening, disease assessment (per RECIST v1.1) included chest and abdomen imaging by computed tomography or magnetic resonance imaging (MRI) with contrast. Contrast-enhanced brain MRI was required at screening and was repeated postbaseline for patients with CNS metastases. A central independent review committee (IRC) reviewed on-study images. Disease was assessed every 8 weeks through cycle 15 (28 days per cycle), and then every 12 weeks until progression. Objective responses were confirmed ≥4 weeks after initial response.

Visits were scheduled to occur on days 1, 8, and 15 of the first 28-day cycle and then every 4 weeks (starting on day 1 of cycle 2), at treatment discontinuation, and at 30 days post-treatment. On days 8 and 15, patients were assessed for early pulmonary symptoms. Follow-up for survival and subsequent therapy continued every 3 months after treatment discontinuation. The protocol includes the assessment schedule.

### Outcomes

The primary end point was confirmed ORR per RECIST v1.1 (per investigator). Secondary end points included confirmed ORR (per central IRC), CNS response (IRC-assessed intracranial confirmed ORR and PFS in patients with active brain metastases), duration of response, PFS, overall survival (OS), safety, tolerability, and patient-reported symptoms of lung cancer and health-related quality-of-life (QoL) scores assessed with the European Organisation for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30, version 3.0), including mean transformed global health status/QoL score (on the basis of questions 29 and 30). Active brain metastases were defined as lesions without prior radiotherapy or with investigator-assessed progression after prior radiotherapy. Intracranial response was defined as a ≥30% decrease in measurable lesions or complete disappearance of lesions in patients with only nonmeasurable lesions.

### Statistical Analysis

A sample size of ≥109 patients in each arm provides approximately 90% power to rule out an ORR of 20% when the true ORR is ≥35% with a two-sided alpha level of 0.025. Efficacy was evaluated in the intention-to-treat population. Patients with baseline brain metastases (by IRC assessment) were included in IRC analyses of intracranial efficacy. Patients who received any brigatinib were included in the safety population. CIs were calculated using the exact binomial method; 97.5% CIs were estimated for other end points. Time-to-event efficacy analyses (duration of response, PFS, and OS), median values and two-sided 95% CIs were estimated using Kaplan-Meier methods. Investigator-assessed efficacy data and all safety data are reported as of February 29, 2016. IRC-assessed whole-body and
intracranial efficacy data had last scan dates of May 16, 2016, and April 14, 2016, respectively. The trial was not designed for statistical comparisons between arms; however, post hoc hazard ratios were estimated for PFS to support dose selection. Statistical analyses were performed using SAS software (version 9.4).

### RESULTS

#### Patients

Between June 4, 2014, and September 21, 2015, 222 patients were enrolled at 71 centers in 18 countries. Patients were randomly assigned to brigatinib in arm A (90 mg once daily; n = 112) or arm B (180 mg with a 7-day lead-in at 90 mg [180 mg once daily (with lead-in)]; n = 110; Fig 1). Three patients in arm A were never treated and are included in intention-to-treat analyses. Overall, arms were balanced for baseline factors, including sex, Eastern Cooperative Oncology Group performance status, brain metastases, prior chemotherapy, and best response to prior crizotinib (Table 1). Of 222 patients, 154 (69%) had brain metastases at baseline per investigators, 164 (74%) had prior chemotherapy, 144 (65%) had a best response of CR or PR to prior crizotinib, and 69 (31%) were Asian. As of February 29, 2016, 64 patients (57%) in arm A and 76 patients (69%) in arm B remained on study treatment, with median (range) follow-ups of 7.8 (0.1 to 16.7) months and 8.3 (0.1 to 20.2) months, respectively.

#### Efficacy

**Investigator-assessed efficacy.** Response rates are shown in Table 2. Investigator-assessed confirmed ORR was 45% (97.5% CI, 34% to 56%) in arm A, including one CR, and 54% (97.5% CI, 43% to 65%) in arm B, including four CRs. Confirmed ORR in patients with prior chemotherapy was 42% (35 of 83 patients) in arm A and 54% (44 of 81 patients) in arm B; in patients without prior chemotherapy, confirmed ORRs were 52% (15 of 29 patients) in each arm. One patient in arm B with a G1202R mutation detected from tumor tissue at baseline had a confirmed PR. The median time to response was rapid: 1.8 months (range, 1.7 to 9.1 months) and 1.9 months (1.0 to 11.0 months) in arms A and B, respectively. As of data cutoff, the median duration of response was 13.8 months (95% CI, 5.6 to 13.8) in arm A (with 14 [28%] events in 50 responders) and 11.1 months (95% CI, 9.2 to 13.8) in arm B (with 12 [20%] events in 59 responders). The change from baseline in target lesions is shown in Fig 2A. Investigator-assessed median PFS was 9.2 months (95% CI, 7.4 to 15.6) and 12.9 months (11.1 to not reached) in arms A and B, respectively (Fig 2B). The PFS hazard ratio was 0.55 (95% CI, 0.35 to 0.86; arm B v A). Preliminary OS estimates are shown in Fig 2C. The 1-year OS probability was 71% (95% CI, 60% to 79%) and 80% (67% to 88%) in arms A and B, respectively.

**IRC-assessed whole-body efficacy.** IRC-assessed confirmed ORR was 48% (95% CI, 39% to 58%) and 53% (95% CI, 43% to 62%), with four and five CRs, in arms A and B, respectively. The median duration of response was 13.8 months (95% CI, 7.4 to not reached) in arm A and 13.8 months (95% CI, 9.3 to not reached) in arm B. The IRC-assessed median PFS was 9.2 months (95% CI, 7.4 to not reached) and 15.6 months (11.0 to not reached) in arms A and B, respectively (Data Supplement).

**IRC-assessed intracranial efficacy.** Of 222 patients, 217 had an IRC-evaluated baseline brain MR image; 153 had baseline brain metastases and 44 had measurable lesions. Table 3 shows intracranial response rates. The IRC-assessed intracranial ORR in patients with measurable baseline brain metastases was 42% (11 of 26 patients; 95% CI, 23% to 63%) in arm A and 67% (12 of 18 patients; 95% CI, 41% to 87%) in arm B. Within each arm, response rates were similar among all patients with measurable baseline brain metastases and those with active brain metastases (lesions without prior radiotherapy or with investigator-assessed progression after prior radiotherapy). In patients with only nonmeasurable baseline brain metastases, 7% (four of 54 patients;
95% CI, 2% to 18%) in arm A and 18% (10 of 55 patients; 95% CI, 9% to 31%) in arm B had complete resolution of intracranial lesions. The change from baseline in measurable brain lesions is shown in Fig 3A. In patients with intracranial response, the median duration of intracranial response was not reached (95% CIs: 3.7 months to not reached, arm A; 5.6 months to not reached, arm B). The median intracranial PFS was 15.6 months (95% CI, 7.3 to 15.7) and 12.8 months (11.0 to not reached) in arms A and B, respectively (Fig 3B).

### Safety

**AEs.** The most common any-grade treatment-emergent AEs (TEAEs) included GI symptoms (nausea, 33%/40% and diarrhea, 19%/38%, in arms A/B, respectively), headache (28%/27%, arms A/B), and cough (18%/34%, arms A/B; Table 4). Some TEAEs seemed to be dose related, although differences were mainly in grade 1 to 2 events. The most common grade $\geq$ 3 TEAEs (excluding neoplasm progression) were hypertension (6%/6%, arms A/B), increased blood creatine phosphokinase (3%/9%, arms A/B),

### Table 1. Patient Demographic Data and Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Arm A, 90 mg Once Daily</th>
<th>Arm B, 180 mg Once Daily (with lead-in)*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>112</td>
<td>110</td>
<td>222</td>
</tr>
<tr>
<td>Median age, years (range)</td>
<td>50.5 (18-82)</td>
<td>56.5 (20-81)</td>
<td>54 (18-82)</td>
</tr>
<tr>
<td>Sex, female, No. (%)</td>
<td>62 (55)</td>
<td>64 (58)</td>
<td>126 (57)</td>
</tr>
<tr>
<td>Race, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>72 (64)</td>
<td>76 (69)</td>
<td>148 (67)</td>
</tr>
<tr>
<td>Asian</td>
<td>39 (35)</td>
<td>30 (27)</td>
<td>69 (31)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (1)</td>
<td>4 (4)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>ECOG performance status, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>34 (30)</td>
<td>45 (41)</td>
<td>79 (36)</td>
</tr>
<tr>
<td>1</td>
<td>71 (63)</td>
<td>56 (51)</td>
<td>127 (57)</td>
</tr>
<tr>
<td>2</td>
<td>7 (6)</td>
<td>9 (8)</td>
<td>16 (7)</td>
</tr>
<tr>
<td>Smoking history, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>40 (36)</td>
<td>47 (43)</td>
<td>87 (39)</td>
</tr>
<tr>
<td>No</td>
<td>71 (63)</td>
<td>63 (57)</td>
<td>134 (60)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (&lt; 1)</td>
</tr>
<tr>
<td>Histology, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>107 (96)</td>
<td>108 (96)</td>
<td>215 (97)</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (&lt; 1)</td>
</tr>
<tr>
<td>Squamous</td>
<td>2 (2)</td>
<td>1 (1)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>Large cell</td>
<td>1 (1)</td>
<td>1 (1)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Mucoepidermoid carcinoma</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (&lt; 1)</td>
</tr>
<tr>
<td>Brain metastases at baseline, † No. (%)</td>
<td>80 (71)</td>
<td>74 (67)</td>
<td>154 (69)</td>
</tr>
<tr>
<td>Prior chemotherapy, No. (%)</td>
<td>83 (74)</td>
<td>81 (74)</td>
<td>164 (74)</td>
</tr>
<tr>
<td>Best response to prior crizotinib, † No. (%)</td>
<td>71 (63)</td>
<td>73 (66)</td>
<td>144 (65)</td>
</tr>
<tr>
<td>CR or PR</td>
<td>28 (25)</td>
<td>21 (19)</td>
<td>49 (22)</td>
</tr>
<tr>
<td>PD</td>
<td>8 (7)</td>
<td>6 (5)</td>
<td>14 (6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>5 (4)</td>
<td>10 (9)</td>
<td>15 (7)</td>
</tr>
<tr>
<td>Median cumulative duration of prior crizotinib regimens, months (range)</td>
<td>11.3 (1-59)</td>
<td>13.2 (1-72)</td>
<td>12.6 (1-72)</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; PR, partial response; SD, stable disease.

*180 mg once daily with 7-day lead-in at 90 mg.

†As assessed by the investigator.

### Table 2. Objective Response and Disease Control Rates by Arm

<table>
<thead>
<tr>
<th>Variable</th>
<th>Investigator-Assessed</th>
<th>IRC-Assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>Arm A, 90 mg Once Daily</td>
<td>Arm B, 180 mg Once Daily (with lead-in)*</td>
</tr>
<tr>
<td>Confirmed ORR, No. (%)</td>
<td>50 (45)</td>
<td>59 (54)</td>
</tr>
<tr>
<td>Confirmed CR, No. (%)</td>
<td>34 to 56†</td>
<td>43 to 65†</td>
</tr>
<tr>
<td>Confirmed PR, No. (%)</td>
<td>49 (44)</td>
<td>55 (50)</td>
</tr>
<tr>
<td>Disease control rate, No. (%)</td>
<td>92 (82)</td>
<td>95 (86)</td>
</tr>
<tr>
<td>95% CI</td>
<td>74 to 89</td>
<td>79 to 92</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; IRC, independent review committee; ORR, objective response rate; PR, partial response.

*180 mg once daily with 7-day lead-in at 90 mg.

†Primary end point tested at 0.025 alpha level for each dose.
Fig 2. Brigatinib whole-body efficacy in crizotinib-refractory ALK-positive NSCLC by arm. (A) The best percentage change from baseline in the sum of the longest diameters of target lesions is reported in patients who had a follow-up scan and were evaluable for response (n = 101, arm A; n = 100, arm B), on the basis of investigator assessment. All study assessments were used in these calculations. The dotted line at –30% indicates the threshold for partial response per RECIST v1.1. The percentages of patients with no reduction, > 0% to 25% reduction, > 25% to 50% reduction, > 50% to 75% reduction, and > 75% to 100% reduction in target lesions were 13%, 20%, 35%, 20%, and 13% in arm A, respectively, and 7%, 23%, 29%, 19%, and 22% in arm B, respectively. (B) Investigator-assessed PFS is shown for the intention-to-treat population. Of the 112 patients in arm A, 50 (45%) had an event; of the 110 patients in arm B, 31 (28%) had an event. (C) Preliminary OS is shown for the intention-to-treat population. Of the 112 patients in arm A, 27 (24%) had an event; of the 110 patients in arm B, 17 (15%) had an event. ALK-positive, anaplastic lymphoma kinase gene-rearranged; NR, not reached; NSCLC, non–small-cell lung cancer; OS, overall survival; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1. (*) 180 mg once daily with 7-day lead-in at 90 mg. (†) Single response awaiting confirmation. (‡) Patient had a lymph node target lesion that resolved to ≤10 mm shortest diameter (complete response per RECIST v1.1). (§) Category includes single responses that were not confirmed.
pneumonia (3%/5%, arms A/B), and increased lipase (4%/3%, arms A/B).

Pulmonary AEs with early onset. A subset of pulmonary AEs with early onset (median time to onset, 2 days [range, 1 to 9 days]) that included dyspnea, hypoxia, cough, pneumonia, or pneumonitis occurred in 14 patients (6%); seven patients (3%) had grade ≥ 3 events (Data Supplement). These AEs occurred at 90 mg, in both arms, and no such events occurred after escalation to 180 mg. They were managed with dose interruption and successful reintroduction of brigatinib in six of 14 patients, and one patient continued treatment with resolution of symptoms after dose reduction to 60 mg once daily without needing interruption. Seven patients discontinued treatment, including one patient who died on day 7, after experiencing dyspnea, cough, and pneumonia. This patient's autopsy revealed lymphangitic carcinomatosis, widespread lung scarring, and diffuse alveolar damage. Pathologist-reported causes of death were lung cancer, adhesive pericarditis, and respiratory failure. A multivariable analysis evaluated the impact of baseline risk factors on the development of pulmonary AEs with early onset (Data Supplement). Older age and shorter time to progression were risk factors for development of pulmonary AEs with early onset at 90 mg and 180 mg, respectively.

Dose modifications. Dose reduction as the result of any AE occurred in 7% (eight of 109) and 20% (22 of 110) of treated patients in arms A and B, respectively. Dose interruption (≥ 3 days) for any reason occurred in 18% (20 of 109) and 36% (40 of 110) of patients in arms A and B, respectively. The median dose intensity was 90 mg per day in arm A and 174 mg per day in arm B. The most common reasons for dose reduction were increased blood creatine phosphokinase (n = 2, arm A/n = 5, arm B), pneumonitis (n = 1, arm A/n = 2, arm B), and rash (n = 1, arm A/n = 2, arm B). Eight patients (4%) died within 30 days of the last dose (excluding those who died as a result of neoplasm progression, malignant pleural effusion, and metastases to meninges). Investigator-reported reasons for death included pneumonia (n = 2; one case was an early pulmonary AE), bacterial meningitis (n = 1), dyspnea (n = 1), pulmonary embolism (n = 1), respiratory failure (n = 1), sudden death (n = 1), and urosepsis (n = 1).

Table 3. Independent Review Committee–Assessed Intracranial Response Rates by Arm

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients With Measurable (≥ 10 mm) Brain Metastases</th>
<th>Patients With Measurable (≥ 10 mm) Active* Brain Metastases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Arm A, 90 mg Once Daily</td>
<td>Arm B, 180 mg Once Daily (with lead-in)†</td>
</tr>
<tr>
<td>No. of patients</td>
<td>26</td>
<td>18</td>
</tr>
<tr>
<td>Confirmed intracranial ORR, No. (%)</td>
<td>11 (42)</td>
<td>12 (67)</td>
</tr>
<tr>
<td>95% CI</td>
<td>23 to 63</td>
<td>41 to 87</td>
</tr>
<tr>
<td>Confirmed intracranial CR, No. (%)</td>
<td>2 (8)</td>
<td>0</td>
</tr>
<tr>
<td>Confirmed intracranial PR, No. (%)</td>
<td>9 (35)</td>
<td>12 (67)</td>
</tr>
<tr>
<td>Intracranial disease control rate, No. (%)</td>
<td>22 (85)</td>
<td>15 (63)</td>
</tr>
<tr>
<td>95% CI</td>
<td>65 to 96</td>
<td>59 to 96</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; ORR, objective response rate; PR, partial response.

*Active brain metastases were defined as lesions without prior radiotherapy or those with investigator-assessed progression after prior radiotherapy.

QoL

The mean transformed global health status/QoL score (on the basis of questions 29 and 30 of EORTC QLQ-C30) gradually increased through approximately month 7 and then slowly declined, but remained higher than baseline values (Data Supplement). No significant differences between arms were observed at baseline or during follow-up.

DISCUSSION

Brigatinib demonstrated substantial efficacy with both regimens. Objective response rates were high, and responses occurred quickly and were durable in both arms. Efficacy outcomes favored the higher dose, most notably in PFS and intracranial responses. At 180 mg (with lead-in at 90 mg), the confirmed ORR was 54% (59 of 110 patients), and the intracranial ORR was 67% for patients with measurable brain metastases. The median PFS was > 1 year by investigator assessment (12.9 months) and by IRC assessment (15.6 months), and the estimated 1-year OS was 80%.

Objective response rates for ALK inhibitors in the post–crizotinib setting (brigatinib, ceritinib, and alectinib) seem similar across most trials, at 50% to 56%, although somewhat different patient populations and methods of assessment limit comparison. These response rates probably reflect comparable activity against dominant crizotinib-resistant clones. However, any differences among these drugs in their ability to suppress clinically relevant ALK mutations, including those that may not be dominant initially but could emerge later, are more likely to be reflected in PFS or duration of response.

In preclinical models, brigatinib had broader predicted mutation coverage, compared with ceritinib and alectinib. Consistent with this observation, in the phase I/II trial of brigatinib, the median PFS of patients with advanced ALK-positive NSCLC who previously received crizotinib (most of whom received 180 mg per day, with or without lead-in at 90 mg) was recently reported as 12.9 months, across all doses tested. This extended PFS, relative to ceritinib12-14 and alectinib15,16 results, is substantiated by the median PFS of > 1 year in arm B of ALTA. Additionally, a patient with the recalcitrant G1202R mutation had a confirmed PR, as predicted by preclinical data. A limitation
of the current study is that the randomized selection design did not include formal statistical PFS and OS comparisons between arms.

The safety profile in this study was consistent with that previously reported for brigatinib22,23 and was acceptable in both arms. The frequency of any individual grade ≥ 3 AE was low in both arms. Dose modifications and discontinuations as the result of AEs were more common with 180 mg (with lead-in). Dose-reduction rates were 20% (arm B) versus 7% (arm A). In contrast, at the recommended starting doses of ceritinib and alectinib, reported dose-reduction rates are 58% and 23%, respectively.26,27 Beyond tolerability, the impact of dose reductions on efficacy, particularly CNS efficacy, should be considered. The intracranial ORR of 67% in patients with measurable brain metastases who received 180 mg (with lead-in) in this study compares favorably with second-generation ALK-inhibitor data.28,29 The CNS benefit seems to be sustained with a median intracranial PFS > 1 year in both arms and the median durations of intracranial response not being reached. Health-related QoL remained at or higher than baseline levels and did not differ between arms.

The current results confirm phase I/II observations regarding pulmonary AEs with early onset.23 In the phase I/II trial, the frequency of these AEs seemed to be related to starting dose; a lead-in dose of 90 mg once daily for 1 week before escalation to 180 mg once daily seemed to reduce the risk of these AEs compared with starting at 180 mg once daily. In ALTA, all early pulmonary AEs occurred at 90 mg (in arm A or before dose escalation in arm B); no such events occurred after escalation to 180 mg in arm B. Therefore, the efficacy of 180 mg (with lead-in) was not associated with an increased risk of additional early pulmonary AEs, compared with 90 mg. Pulmonary toxicity, including pneumonitis and interstitial lung disease, has been observed with crizotinib, ceritinib, and alectinib in similar patient populations26,27,30; however, rapid onset in the small subset of brigatinib-treated patients with these AEs, and the potential to tolerate and continue dosing, suggest a different underlying etiology that is unknown. Patients
treated with brigatinib should be monitored for new or worsening respiratory symptoms, particularly during the first week of treatment. Management of early pulmonary AEs should include dose interruption and prompt clinical evaluation.

In conclusion, efficacy and safety in the phase II ALTA trial support future trials with the 180-mg regimen (with lead-in at 90 mg). On the basis of these results, brigatinib seems to be a promising new treatment option for crizotinib-refractory ALK-positive NSCLC. Brigatinib is currently being investigated in a randomized, phase III trial of brigatinib (180 mg [with lead-in]) versus crizotinib in ALK inhibitor–naïve patients (ALTA-1L; ClinicalTrials.gov identifier: NCT02737501).

Table 4. Treatment-Emergent Adverse Events Reported in ≥ 10% of All Patients

<table>
<thead>
<tr>
<th>Treatment-Emergent Adverse Event</th>
<th>Arm A, 90 mg Once Daily, n = 109</th>
<th>Arm B, 180 mg Once Daily (with lead-in), n = 110</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade, No. (%)</td>
<td>Grade ≥ 3, No. (%)</td>
</tr>
<tr>
<td>GI disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>36 (33)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>21 (19)</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>26 (24)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Constipation</td>
<td>21 (19)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>18 (17)</td>
<td>0</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>30 (28)</td>
<td>0</td>
</tr>
<tr>
<td>General disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>22 (20)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>15 (14)</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>20 (18)</td>
<td>0</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>23 (21)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>13 (12)</td>
<td>0</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>15 (14)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Back pain</td>
<td>11 (10)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased blood creatine phosphokinase</td>
<td>12 (11)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Increased amylase</td>
<td>9 (8)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>9 (8)</td>
<td>0</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>8 (7)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>24 (22)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>12 (11)</td>
<td>6 (6)</td>
</tr>
</tbody>
</table>

NOTE. The median time on treatment was 7.5 months in arm A and 7.8 months in arm B.

*180 mg once daily with 7-day lead-in at 90 mg.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at jco.org.

REFERENCES


AUTHOR CONTRIBUTIONS


Collection and assembly of data: All authors

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

© 2017 by American Society of Clinical Oncology

Downloaded from ascopubs.org by Bibliothek Der Rijksuniversiteit on October 10, 2017 from 129.125.166.126
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Kim et al


Affiliations

Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smits, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodriguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO.

Prior Presentation

Presented in part at the 52nd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3–7, 2016, and at the 18th National Congress of the Italian Association of Medical Oncology, Rome, Italy, October 28–30, 2016. Also presented in part at the 17th World Conference on Lung Cancer, Vienna, Austria, December 4-7, 2016.
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Dong-Wan Kim
No relationship to disclose

Marcello Tiseo
Honoraria: ARIAD
Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Novartis, Otsuka, Pierre Fabre
Research Funding: ARIAD

Myung-Ju Ahn
Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, MSD, Novartis
Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, MSD, Novartis

Karen L. Reckamp
Consulting or Advisory Role: Amgen, Boehringer Ingelheim, ARIAD, Astellas Pharma, Nektar, Euclises
Research Funding: GlaxoSmithKline (Inst), Bristol-Myers Squibb (Inst), Pfizer (Inst), Novartis (Inst), ARIAD (Inst), Eisai (Inst), Clovis Oncology (Inst), Xcovery (Inst), Gilead Sciences (Inst), Pfizer, Adaptimmune (Inst), Genentech (Inst)

Karin Holmskov Hansen
Honoraria: AstraZeneca, Boehringer Ingelheim, MSD, Roche, Eli Lilly
Consulting or Advisory Role: Boehringer Ingelheim, Eli Lilly, MSD, AstraZeneca, Bristol-Myers Squibb, Roche
Travel, Accommodations, Expenses: Bristol-Myers Squibb, Boehringer Ingelheim, MSD, Pfizer, Pierre Fabre

Sang-We Kim
No relationship to disclose

Rudolf M. Huber
Honoraria: ARIAD, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Roche
Consulting or Advisory Role: Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Eli Lilly, Novartis, Roche
Research Funding: Pierre Fabre

Howard L. West
Consulting or Advisory Role: Celgene, Merck, Genentech, ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb
Speakers’ Bureau: ARIAD, Genentech, Bristol-Myers Squibb

Harry J.M. Groen
Consulting or Advisory Role: Pfizer (Inst), Novartis (Inst), Bristol-Myers Squibb (Inst), MSD Oncology (Inst), Eli Lilly (Inst), AbbVie (Inst), Genentech (Inst)
Research Funding: Eli Lilly (Inst), Roche (Inst)

Maximilian J. Hochmair
No relationship to disclose

Natasha B. Leighl
Research Funding: Novartis
Travel, Accommodations, Expenses: AstraZeneca, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb

Scott N. Gettinger
Consulting or Advisory Role: Bristol-Myers Squibb, ARIAD, Janssen
Research Funding: Bristol-Myers Squibb, ARIAD, AstraZeneca, MedImmune, Boehringer Ingelheim, Incyte, Pfizer, Genentech

Corey J. Langer
Honoraria: Bristol-Myers Squibb, Genentech, Eli Lilly/ImClone
Consulting or Advisory Role: Genentech, Eli Lilly/ImClone, Merck, Abbott Biotherapeutics, Bayer/Onyx, Clarient, Clovis Oncology, Celgene, Cancer Support Community, Bristol-Myers Squibb, ARIAD, AstraZeneca
Research Funding: Merck (Inst), Advantagene (Inst), Clovis Oncology (Inst), Celgene (Inst), Inovio Pharmaceuticals (Inst), ARIAD (Inst), GlaxoSmithKline (Inst), Genentech (Inst), Stemcentrx (Inst)

Luis G. Paz-Ares Rodríguez
Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Pfizer, Roche

Egbert F. Smit
Consulting or Advisory Role: Boehringer Ingelheim, Eli Lilly, MSD

Edward S. Kim
Consulting or Advisory Role: Eli Lilly, Celgene, AstraZeneca, Boehringer Ingelheim

William Reichmann
Employment: ARIAD
Stock or Other Ownership: ARIAD

Frank G. Haluska
Employment: ARIAD, BioCancell
Leadership: ARIAD, BioCancell
Stock or Other Ownership: ARIAD, BioCancell

David Kerstein
Employment: ARIAD
Stock or Other Ownership: ARIAD

D. Ross Camidge
Honoraria: ARIAD
Research Funding: ARIAD
Acknowledgment

We thank the patients, their families, their caregivers, and the investigators and their team members for participation in the ALTA trial. We also thank the members of the study team (ARIAD Pharmaceuticals) and Jessica Tyler (ARIAD Pharmaceuticals) for editorial assistance. Professional medical writing assistance was provided by Pamela Barendt (Peloton Advantage, Parsippany, NJ) and funded by ARIAD Pharmaceuticals.